A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Clinical trial NCT07372625 · RECRUITING
Trial details
- NCT number
- NCT07372625
- Sponsor
- PMV Pharmaceuticals, Inc
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-04
- Primary completion
- 2027-03-01
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.